Question 1

Which of the following statements about uric acid is true?

Accepted Answer

A)  It is a product of pyrimidine-based nucleic acid metabolism. 
B)  It tends to crystallise at relatively low physiological temperatures. 
C)  Hyperuricaemia always results in gout. 
D)  Uric acid is very water-soluble in kidney filtrate. 
A)  It is a product of pyrimidine-based nucleic acid metabolism. 
B)  It tends to crystallise at relatively low physiological temperatures. 
C)  Hyperuricaemia always results in gout. 
D)  Uric acid is very water-soluble in kidney filtrate. B

Question 2

When commencing a uricosuric agent such as probenecid,the person should be advised to:

Accepted Answer

A)  cease all other medications to reduce drug interactions. 
B)  ensure adequate fluid intake to reduce kidney stone formation. 
C)  avoid direct sunlight. 
D)  avoid urine alkalising preparations. 
A)  cease all other medications to reduce drug interactions. 
B)  ensure adequate fluid intake to reduce kidney stone formation. 
C)  avoid direct sunlight. 
D)  avoid urine alkalising preparations. B

Question 3

Which of the following tests is undertaken before using colchicine for gout prophylaxis?

Accepted Answer

A)  A complete blood count 
B)  A liver function test 
C)  An electrocardiogram 
D)  An exercise tolerance test 
A)  A complete blood count 
B)  A liver function test 
C)  An electrocardiogram 
D)  An exercise tolerance test A

Question 4

To minimise the increased incidence of acute gouty attacks at the start of allopurinol treatment,________ should be given concurrently for the first two months of treatment.

Accepted Answer

A)  colchicine or an NSAID 
B)  probenecid 
C)  an intra-articular injection of methylprednisolone 
D)  a urinary alkaliser such as sodium bicarbonate 
A)  colchicine or an NSAID 
B)  probenecid 
C)  an intra-articular injection of methylprednisolone 
D)  a urinary alkaliser such as sodium bicarbonate

Question 5

A characteristic of gout is that:

Accepted Answer

A)  it manifests as a form of arthritis. 
B)  it is more prevalent in women. 
C)  the risk of developing it can be reduced by eating foods such as sardines or offal. 
D)  it is not associated with any genetic predisposition. 
A)  it manifests as a form of arthritis. 
B)  it is more prevalent in women. 
C)  the risk of developing it can be reduced by eating foods such as sardines or offal. 
D)  it is not associated with any genetic predisposition.

Question 6

Colchicine has NSAID properties,but also has specific mechanisms including ________ to treat gout.

Accepted Answer

A)  stimulating prostaglandin synthesis and secretion 
B)  disruption of leukocyte microtubule function, which inhibits cell migration to the site of inflammation 
C)  activation of xanthine oxidase 
D)  creating more acidic urine, which increases excretion of uric acid 
A)  stimulating prostaglandin synthesis and secretion 
B)  disruption of leukocyte microtubule function, which inhibits cell migration to the site of inflammation 
C)  activation of xanthine oxidase 
D)  creating more acidic urine, which increases excretion of uric acid

Question 7

Which one of the following drugs or drug groups acts to increase the excretion of uric acid?

Accepted Answer

A)  The corticosteroids 
B)  Colchicine 
C)  Probenecid 
D)  Allopurinol 
A)  The corticosteroids 
B)  Colchicine 
C)  Probenecid 
D)  Allopurinol

Question 8

Prior to commencing probenecid for gout,it is important to inform the person that:

Accepted Answer

A)  probenecid is inactivated by pigments in red food colouring, so they must abstain from foods containing red dye three days prior to commencement of therapy and throughout the course of therapy. 
B)  probenecid is likely to cause constipation. 
C)  ceasing oral analgesics is the best way to gauge the effect of a course of probenecid. 
D)  probenecid is a preventive treatment and should not be commenced while they have acute symptoms of gout. 
A)  probenecid is inactivated by pigments in red food colouring, so they must abstain from foods containing red dye three days prior to commencement of therapy and throughout the course of therapy. 
B)  probenecid is likely to cause constipation. 
C)  ceasing oral analgesics is the best way to gauge the effect of a course of probenecid. 
D)  probenecid is a preventive treatment and should not be commenced while they have acute symptoms of gout.

Exam 65: Hyperuricaemia and Gout

Which of the following statements about uric acid is true?

When commencing a uricosuric agent such as probenecid,the person should be advised to:

Which of the following tests is undertaken before using colchicine for gout prophylaxis?

To minimise the increased incidence of acute gouty attacks at the start of allopurinol treatment,________ should be given concurrently for the first two months of treatment.

A characteristic of gout is that:

Colchicine has NSAID properties,but also has specific mechanisms including ________ to treat gout.

Which one of the following drugs or drug groups acts to increase the excretion of uric acid?

Prior to commencing probenecid for gout,it is important to inform the person that:

Sociocultural Aspects

Health Professionals and the Law

Ethical Issues

the Roles and Responsibilities of Health Professionals in Medicine Adherence, Education and Advocacy

the Roles and Responsibilities of Health Professionals in Medicine Management

Medicine Formulations, Storage and Routes of Administration

the Clinical Decision-making Process

Medicine Administration Strategies and Documentation

Medication Errors

Management of Common Adverse Drug Reactions

Risk Communication: Balancing the Benefits and Risks of Drug Treatment

Drug Nomenclature

Pharmacokinetics: Absorption and Distribution

Pharmacokinetics Metabolism and Excretion

Drug Interactions

Pharmacodynamics

Drug Development, Evaluation and Safety

Genetic Considerations in Pharmacology

Pharmacokinetic Factors That Modify Drug Action

Paediatric and Geriatric Pharmacology

Poisoning and Envenomation

the Management of Acute Clinical Overdose

Contemporary Drugs of Abuse

Drug Abuse in Sport

General Aspects of Neuropharmacology

Adrenergic Pharmacology

Cholinergic Pharmacology

An Introduction to Chemical Mediators

Histamine and Antihistamines

Prostaglandins and Serotonin

Nitric Oxide and the Endothelins

General concepts of Psychopharmacology

Antipsychotics

Anxiolytics and Hypnotics

Antidepressants and Mood Stabilisers

Medicines Used in Neurodegenerative Disorders

Antiseizure Agents and Muscle Relaxants

Central Nervous System Stimulants

Opioid Analgesics

Anti-inflammatory, Antipyretic and Non-opioid Analgesic Agents

Medicines Used to Treat Migraine

General Anaesthesia

Local Anesthesia

Medicines Used to Lower Blood Lipids

Antihypertensive Agents

Medicines Used to Promote Tissue Perfusion

Antithrombotic, Fibrinolytic and Haemostatic Agents

Diuretics and Other Renal Medicines

Topic: Medicines Used to Treat Heart Failure

Medicines Used to Treat Cardiac Dysrhythmia

Fluid and Potassium Imbalances

Antianaemic Agents

Medicines Used to Maintain Gas Exchange

Medicines for Upper Respiratory Tract Conditions

Upper Gastrointestinal Tract Medicines

Lower Castrointestinal Tract Medicines

Antiemetic Agents

Enteral and Parenteral Nutrition

Medicines and the Pituitary Gland

Medicines and the Thyroid

Medicines and the Pancreas

Medicines Affecting the Adrenal Cortex

Medicines and the Gonads

Medicines and Bone Metabolism

Obesity and Its Treatment

Introduction to Chemotherapy

Sulfonamides and Trimethoprim

Antibacterial Agents

Antituberculotic and Antileprotic Agents

Antiseptics and Disinfectants

Antiparasitic Agents